Boston Scientific raises sales forecast after strong Q3 results and FDA approval of new Afib device

Boston Scientific has raised its sales outlook after reporting strong third-quarter results, with a profit of $939 million and sales of $4.2 billion, exceeding Wall Street expectations. The company noted a 24.6% revenue growth in its cardiovascular division. The U.S. Food and Drug Administration recently approved the Farawave Nav Ablation Catheter, which allows doctors to map and treat atrial fibrillation using a single device. This innovation replaces the need for a separate mapping catheter, streamlining the procedure. Boston Scientific's sales of the Watchman device also increased by 18%, with over 500,000 patients treated globally. The company completed its acquisition of Silk Road Medical for $1.16 billion and now expects full-year sales growth of about 15%.